Personalized Medicine Coalition
Overview
Introgen Therapeutics (NASDAQ: INGN) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. We are developing product candidates to treat a wide range of cancers using non-integrating tumor suppressors, cytokines and genes. These agents are designed to increase production of normal cancer-fighting proteins that act to overpower cancerous cells, stimulate immune activity. Product candidates can be used alone and also to enhance conventional cancer therapies such as surgery, chemotherapy, radiation and monoclonal antibodies. The Company has treated hundreds of patients with thousands of doses of its tumor suppressor lead product candidate ADVEXIN in approximately 30 completed and ongoing Phase 1, Phase 2, and Phase 3 clinical trials worldwide. INGN 241 is in Phase 1-2 clinical development, INGN 225, an immunotherapy, is in Phase 1-2 clinical development...
Corporate Structure
CHIEF EXECUTIVE OFFICER
TOP EXECUTIVES
William P. Egan Board of Directors
Vaughn M. Kailian Board of Directors
Phyllis E. Whiteley Senior Vice President, Business Development and Li
Dennis L. Winger Board of Directors
Bill Ericson Board of Directors
Charles A. Sanders Board of Directors
Sharon Terry Board of Directors
John E Osborn Executive Vice President, General Counsel & Secret
Lesley Russell Executive Vice President and Chief Medical Officer
Jeffry L. Vaught PhD Executive Vice President and Chief Scientific Officer
Carl Savini Executive Vice President & Chief Administrative Officer
Robert P. Roche Executive Vice President, Worldwide Pharmaceutical Operations
Michael D. Goldberg Board of Directors
Geoffrey S Ginsburg Board of Directors
Kevin E. Moley Board of Directors
Joseph D McInerney Executive Director, National Coalition for Health Professional Education In Genetics (Nchpeg)
Robert Wells Board of Directors
Joanne Armstrong Board of Directors
Edward Abrahams Executive Director
Wayne A Rosenkrans JR Board of Directors
Paul Landauer Board of Directors
J Brian Munroe Elected President and Chairman of Personalized Medicine Coalition for Second Term
Denny Van Liew Board of Directors
Patrick Terry Co-Founder and Director of Consumer Advocacy, Genomic Health
Randy Burkholder Associate Vice President, Policy, Phrma
Brett J Davis Board of Directors
Nancy A. Simonian Board of Directors
Gualberto Ruano Session Chair
Ernst Berndt Session Chair
Dale Halsey Lea Assistant Director, Southern Maine Genetic Services
Frank Douglas Session Chair
Peter E. Grebow Executive Vice President, Worldwide Technical Operations
Stephen Furlong Board of Directors
Mara G Aspinall Board of Directors
Steve Seelig Board of Directors
Walter Moore Board of Directors
Dee Simons Board of Directors
Geoff Ginsburg Board of Directors
Stephen A Merrill Executive Director, Board on Science
Bryan Luce Senior Research Leader & Chairman of the Board, Medtap International
Bruce Artim Board of Directors
Larry Lesko Board of Directors
Jerry Collins Board of Directors
Gerald J Pappert Executive Vice President & General Counsel
Valli F. Baldassano Esq Executive Vice President, Chief Compliance Officer
Martyn D. Greenacre Board of Directors
Stan Finkelstein Senior Research Scientist
Sean Tunis Director of The Office of Clinical Standards and Quality and Chief Medical Officer at Cms
Christy White Principal and Founder, Cogent Research
Andrew Von Eschenbach Acting Commissioner, U.S. Food and Drug Administration
Louis Seley Prof of Applied Economics
Donald Rucker Vice President and Chief Medical Officer, Siemens
Ned McCulloch Senior Program Manager, IBM
Norman Kahn Jr Vice President, Science and Education, Director of Medical Education, Cme
Howard Levy Internist, Johns Hopkins Medicine
Felix Frueh Vice President
Rachel Levinson Director for Life Sciences, Office of Science &Technology Policy
David Whitehouse Chief Medical Officer, Strategy & Innovation, United Behavioral Health
Cheryl Madsen Senior Manager, Regulatory Affairs, Genentech
Jeffrey Cossman Board of Directors
G Raab Consultant
Gail R Wilensky Board of Directors
Steven Gutman Supervisory Medical Officer, Cdrh, Fda
David Veenstra Assistant Prof, Pharmaceutical Outcomes Research and Policy Program
